Source-grounded facts extracted from Lexeo Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Lexeo Therapeutics, Inc. reported the first quarter 2026 results: net income Net loss was $20.2 million or $0.25 per share (basic and diluted) for the three months ended March 31, 2026, EPS $0.25 per share (basic and diluted).
“Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights”
Dr. Laura Sepp-Lorenzino was appointed as Director at Lexeo Therapeutics, Inc..
“On April 28, 2026 (the “ Appointment Date ”), Dr. Laura Sepp-Lorenzino was appointed to the board of directors (the “ Board ”) of Lexeo Therapeutics, Inc.”
Lexeo Therapeutics, Inc. reported financial results for the fourth quarter and full year 2025.
“On March 30, 2026, Lexeo Therapeutics, Inc. (the “ Company ”) issued a press release announcing business highlights and its financial results for the three and twelve months ended December 31, 2025.”
Lexeo Therapeutics, Inc. issued 15,625,000 shares of Common Stock, plus an over-allotment option for up to 2,343,750 additional shares of common stock to the several underwriters for gross proceeds of approximately $125 million, at a price to the public of $8.00 per share, underwriter purchase price $7.52 per share.
“On October 16, 2025, Lexeo Therapeutics, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC, as representative (the “ Representative ”) of the several underwriters named therein (collectively, the “ Underwriters ”), relating to the issuance and sale in a public offering (the “ Public Offering ”) of 15,625,000 shares (the “ Firm Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), at a price to the public of $8.00 per share.”
Lexeo Therapeutics, Inc. issued pre-funded warrants to purchase 1,250,015 shares of Common Stock of warrant to a qualified institutional buyer for aggregate gross proceeds of approximately $10 million, at $7.9999 per Pre-Funded Warrant.
““ Public Offering ”) of 15,625,000 shares (the “ Firm Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), at a price to the public of $8.00 per share. Under the terms of the Underwriting Agreement, the Underwriters have agreed to purchase the Firm Shares from the Company at a price of $7.52 per share. In addition, the”
Tolga Tanguler was appointed as director at Lexeo Therapeutics, Inc..
“On November 11, 2024 (the “ Appointment Date ”), Tolga Tanguler was appointed to the board of directors of the Company (the “ Board ”).”
Tim Van Hauwermeiren was appointed as Director at Lexeo Therapeutics, Inc..
“On July 5, 2024 (the “Appointment Date”), Tim Van Hauwermeiren was appointed to the board of directors (the “Board”) of Lexeo Therapeutics, Inc. (the “Company”).”
Lexeo Therapeutics, Inc. reported first quarter 2024 results: net income $21.7 million or $0.77 per share (basic and diluted), EPS $0.77 per share (basic and diluted).
“Net loss was $21.7 million or $0.77 per share (basic and diluted) for the three months ended March 31, 2024”
Lexeo Therapeutics, Inc. entered into Third License Agreement with Cornell University valued at $600,000 (effective 2024-04-21).
“On April 21, 2024, Lexeo Therapeutics, Inc. (the “Company”) entered into the Third License Agreement (the “License Agreement”) with Cornell University”
Bernard Davitian departed as Director at Lexeo Therapeutics, Inc..
“On April 16, 2024, Bernard Davitian notified Lexeo Therapeutics, Inc. (the “Company”) that he does not intend to stand for reelection at the Company’s 2024 annual meeting of stockholders on June 25, 2024.”
Lexeo Therapeutics, Inc. reported financial results for fourth quarter and full year 2023.
“On March 11, 2024, the Company issued a press release announcing business highlights and its financial results for the three and twelve-months ended December 31, 2023.”
Lexeo Therapeutics, Inc. entered into Common Stock Purchase Agreement with certain qualified institutional buyers and institutional accredited investors valued at approximately $95 million (effective 2024-03-11).
“On March 11, 2024, Lexeo Therapeutics, Inc. (the “ Company ”) entered into a Common Stock Purchase Agreement (the “ Purchase Agreement ”) for a private placement (the “ Private Placement ”) with certain qualified institutional buyers and institutional accredited investors (each, a “ Purchaser ” and collectively, the “ Purchasers ”).”
Lexeo Therapeutics, Inc. reported financial results for the three and nine-months ended September 30, 2023.
“On December 11, 2023, Lexeo Therapeutics, Inc. (the " Registrant ") issued a press release announcing business highlights and its financial results for the three and nine-months ended September 30, 2023.”
Lexeo Therapeutics, Inc.: Adopted amended and restated bylaws effective upon the closing of the IPO (effective 2023-11-07).
“the Company adopted amended and restated bylaws (the “ Restated Bylaws ”) in connection with the closing of the IPO.”
Lexeo Therapeutics, Inc.: Filed amended and restated certificate of incorporation effective as of immediately prior to the closing of the IPO.
“the Company filed an amended and restated certificate of incorporation (the “ Restated Certificate ”) with the Secretary of State of the State of Delaware.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.